| Bioactivity | HBV-IN-41 (compound 45) is a potent and orally active Hepatitis B Virus (HBV) inhibitor, with an EC50 of 0.027μM[1]. |
| In Vivo | HBV-IN-41 (compound 45) (20 mg/kg，口服，每天两次(BID)，持续一周) 通过口服给药可抑制 HBV AAV 小鼠模型中的 HBV DNA 病毒载量[1]。 |
| Name | HBV-IN-41 |
| CAS | 1967002-25-0 |
| Formula | C18H19ClFN5O3 |
| Molar Mass | 407.83 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kou B, et al. Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B Virus. J Med Chem. 2023 Oct 6. |